Biomedical subjects

M Loebe

Publications and source records attributed to M Loebe.

92 records · Page 6Linked to original sources

PubMedDate not supplied

Coronary artery disease in patients with hearts from older donors: morphologic features and therapeutic implications.

Of 558 heart transplant recipients, 234 long-term survivors (more than 12 months) were studied by annual catheterization to evaluate the risk of postoperative coronary artery disease in hearts from older donors. No significant difference was found in graft function between hearts from younger and older donors (group I: n = 157, mean donor age 23 +/- 5 years, mean follow-up 45 +/- 22 months; group II: n = 77, mean donor age 43 +/- 5 years, mean follow-up 42 +/- 22 months) as indicated by left and right ventricular ejection fraction, pulmonary artery pressure, and pulmonary capillary wedge pressure. Two morphologic patterns of coronary artery disease were observed: a diffuse type of concentric narrowing of the arteries (type 1) and a focal type with proximal single-vessel stenosis (type 2). Type 1 occurred in eight patients (5%) in group I and in four patients in group II (5%) (p = not significant). Type 1 coronary artery disease led to graft failure in seven patients in group I and two patients in group II. Type 2 coronary artery disease occurred in seven patients (4%) in group I and in 14 (18%) in group II (p < 0.001). No death was related to graft failure in patients with type 2 coronary artery disease. Eight patients with type 2 coronary artery disease were successfully treated by percutaneous transluminal coronary angioplasty; one patient underwent coronary artery bypass grafting. Hearts from older donors provide normal graft function. The risk of diffuse coronary artery disease is not elevated in comparison to hearts from younger donors. The higher incidence of focal coronary artery disease suggests donor-transmitted disease that can successfully be treated by conventional therapy.

Actuarial Analysis↗

PubMedDate not supplied

Heparin induced thrombocytopenia. Experiences in 12 heart surgery patients.

A heparin induced thrombocytopenia Type II (HIT) is a dangerous complication of heparin therapy. Bleeding, but above all serious thromboembolic complications, which may result in crippling disabilities or even death, can develop. Twelve heart surgery patients who were diagnosed with a HIT Type II are reported. Seven of the patients were diagnosed post operatively, the other five pre-operatively. Two of these patients underwent heart surgery with r-Hirudin (Behringwerke AG, Marburg, Germany) on cardiopulmonary bypass and two on Orgaran (AKZO Organon, the Netherlands). Of the seven post operative HIT patients, four had had a bypass operation and each had received a mitral or aortic valve replacement. Another patient had received an artificial biventricular support system (Berlin Heart) and was diagnosed with HIT Type II post operatively. Because of his special condition, this patient underwent anticoagulation with Orgaran and heart transplantation with Orgaran on a heart lung machine. Upon suspicion of HIT Type II, heparin therapy was immediately halted and an alternative treatment of Orgaran or r-Hirudin was begun. One patient encountered bleeding of a gastric ulcer on Orgaran therapy. Heart surgery patients, especially patients with an artificial support system, are potentially lethally threatened by serious thromboembolic complications accompanying HIT Type II. Therefore, these patients must be diagnosed as early as possible. Orgaran along with r-Hirudin are effective heparin substitutes in patients with HIT Type II. These medications can be widely administered to heart surgery patients pre-, intra-, and post operatively without complication.

Adult↗